Published in Women's Health Weekly, September 29th, 2005
"Certain anthracycline-containing adjuvant chemotherapy regimens are associated with improved relapse-free survival (RFS) and overall survival (OS) compared with the classic regimen of cyclophosphamide, methotrexate, and fluorouracil in women with early-stage breast cancer," according to scientists in Canada.
The study designed was described by M. N. Levine and colleagues: "Between 1989 and 1993, 710 pre-and perimenopausal women with axillary node-positive breast cancer were randomly assigned to either cyclophosphamide 75 mg/m2 orally days 1 through...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly